| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8097651 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
| US7759394 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8927604 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
| US9827197 | ASSERTIO | Diclofenac formulations and methods of use |
Jun, 2026
(2 years from now) | |
Cambia is owned by Assertio.
Cambia contains Diclofenac Potassium.
Cambia has a total of 4 drug patents out of which 0 drug patents have expired.
Cambia was authorised for market use on 17 June, 2009.
Cambia is available in for solution;oral dosage forms.
Cambia can be used as acute treatment of migraine attacks with or without aura in adults.
The generics of Cambia are possible to be released after 16 June, 2026.
Drugs and Companies using DICLOFENAC POTASSIUM ingredient
Market Authorisation Date: 17 June, 2009
Treatment: Acute treatment of migraine attacks with or without aura in adults
Dosage: FOR SOLUTION;ORAL
CAMBIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic